Biotech: Page 32

  • A wooden figurine of a business person sits at a higher spot on a table than a series of six other wooden figurines of business people.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Making Moves

    BIO’s interim CEO and Alvotech’s new chief quality officer could spell big changes for biotech

    What these life science organizations’ latest executive-level appointments mean for the industry.

    By Karissa Waddick • Oct. 14, 2022
  • Subvariant virus spreading as viral pathogens
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    Coming out of stealth, RIGImmune aims to catch up with ever-mutating viruses

    President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.

    By Kelly Bilodeau • Oct. 13, 2022
  • digital pill Explore the Trendlineâž”
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trendline

    Artificial intelligence & machine learning

    After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

    By PharmaVoice staff
  • Green capsule medicine pill fall out of a production line.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Robotic pills could open a world of possibilities for the biologics market

    As the oral biologic market heats up, Rani Therapeutics is looking to dominate the field with its robotic pill for treatment of chronic conditions. 

    By Karissa Waddick • Oct. 13, 2022
  • Ameet Mallik horizontal
    Image attribution tooltip
    Permission granted by Ameet Mallik
    Image attribution tooltip
    Q&A

    Where the CEO of ADC Therapeutics sees ‘huge potential’ in the tech beyond oncology

    The “magic bullet” approach of ADCs has been a breakthrough in cancer care — but this excitement could be just the beginning.

    By • Oct. 12, 2022
  • Young African American biochemist using microscope while working on scientific research in a laboratory. The view is through the glass.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Citius Pharmaceuticals sees golden opportunities in late-stage specialty assets

    CEO Leonard Mazur explains how the company’s hoping to unlock the potential of its varied pipeline.

    By Karissa Waddick • Oct. 11, 2022
  • Amit Etkin horizontal
    Image attribution tooltip
    Permission granted by Amit Etkin
    Image attribution tooltip
    Profile

    Harnessing the creative energy of California, Alto is advancing a novel approach to psychiatric meds

    After making the leap from academia to the world of biotech, CEO Dr. Amit Etkin is hoping to shift the treatment paradigm for neurological conditions.

    By Alexandra Pecci • Oct. 11, 2022
  • Silhouettes of two people colored in a swirling spectrum of colors. They are against a background of other spectrum colors and shapes.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A

    New partnership may give MDMA an edge in the psychedelics space

    While LSD and psilocybin steal the spotlight, drug developers are also exploring MDMA for a wide swath of neurological illnesses. 

    By Kelly Bilodeau • Oct. 10, 2022
  • Closeup shot of an unrecognizable doctor using a digital tablet.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    The digital therapeutics revolution is happening and Big Pharma is buying in — with caution

    Companies like Pfizer, Novartis, Sanofi and BMS are diving into the world of digital therapeutics while recognizing the limitations of the young field.

    By Michael Gibney • Oct. 10, 2022
  • bad boss
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Opinion

    Are you a bad boss?

    Pharma execs share their tips for being a better leader.

    By • Oct. 7, 2022
  • Professional headshot of Erin Duffy
    Image attribution tooltip

    Permission granted by Asia Kepka

    Image attribution tooltip
    Q&A

    Her antibiotic company failed. Now she’s helping others avoid the same fate.

    The chief of R&D at CARB-X explains why she believes small antibiotics companies can succeed despite market turmoil.

    By Karissa Waddick • Oct. 6, 2022
  • A wood cutout of a person wearing a tie, holding a telescope and standing on a set of four arrows of differing sizes.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Making Moves

    C-suite shake-ups at 23andMe, Moderna signal new stages of growth

    With their latest personnel moves, these life sciences companies are preparing for major business shifts.

    By Karissa Waddick • Oct. 5, 2022
  • cell therapy infusion
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A

    It’s electric — speeding up the cell therapy process for scalability

    To improve the development of cell therapy-based treatments, many companies are turning to a technology that uses electric fields.

    By Alexandra Pecci • Oct. 4, 2022
  • Cancer cells
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    To stay on the leading edge of oncology, AbbVie knows it has to take risks

    In a field that has seen rapid progress but ongoing areas of unmet need, AbbVie is betting on emerging tech.

    By Kelly Bilodeau • Oct. 4, 2022
  • hiring stock
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    The 2 areas in life sciences most in need of talent

    The industry is feeling the hiring crunch — here’s what pharma companies can do to mitigate the impact.

    By • Oct. 4, 2022
  • digital clinical trials
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A

    Clinical trials haven’t harnessed the digital revolution — TransCelerate’s latest initiative aims to change that

    The nonprofit’s VP of portfolio management discussed its “most transformative” digital initiative to date.

    By PharmaVoice staff • Oct. 3, 2022
  • A scale is foregrounded against the sky.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    How do Biogen-Eisai’s two Alzheimer’s drugs stack up?

    Biogen and Eisai's newest Alzheimer's success begs comparison to their past debacle — and bolsters the amyloid theory.

    By Michael Gibney • Sept. 30, 2022
  • Samantha Dale Strasser headshot
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Image attribution tooltip
    Podcast

    Woman of the Week: Pepper Bio’s Samantha Dale Strasser

    The co-founder of Pepper Bio entered the biotech world three years ago with the goal of transforming drug discovery through the emerging discipline of transomics.

    By • Sept. 28, 2022
  • Autism stock
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A

    Why precision medicine could be the next frontier in treating autism

    Swiss-based Stalicla is banking on an AI-driven precision medicine discovery platform to deliver needed therapies in the autism space.

    By Kelly Bilodeau • Sept. 27, 2022
  • Katharine Knobil
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Image attribution tooltip
    Podcast

    Woman of the Week: Agilent Technologies’ Dr. Katharine Knobil

    As the first chief medical officer of the diagnostic testing company, Dr. Katharine Knobil is focused on moving the science forward beyond precision oncology to liquid biopsy.

    By • Sept. 14, 2022
  • Colonies of bacteria in MacConkey agar
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Feds could soon bring COVID-style fight to superbug threat

    COVID-19 has inspired renewed urgency in the need for weapons to combat antimicrobial resistant infections and new hope of government funding to meet the challenge.

    By Karissa Waddick • Sept. 13, 2022
  • Bubble
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    From the ‘go-go days’ to a bubble crunch — the biotech sector faces its next challenge

    The highs of the sector in early 2021 gave way to a bear market that persisted into the second half of this year — but there's hope the bubble hasn't popped for good.

    By Michael Gibney • Sept. 12, 2022
  • Cindy Mesaros
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Image attribution tooltip
    Podcast

    Woman of the Week: Foresite Capital’s Cindy Mesaros

    The longtime marketing pro details her fascinating career journey and how she’s positioning early stage health companies to thrive. 

    By • Sept. 7, 2022
  • CFO
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    First 90 Days

    First 90 Days: Adaptive Biotech’s Tycho Peterson

    A long-time analyst, Tycho Peterson brings his business savvy to the C-suite at Adaptive, where he began as CFO in June with a knowledge of what works and what doesn't in the diagnostics space.

    By Michael Gibney • Sept. 1, 2022
  • A 3D illustration of sickled cells in blood
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Pharma’s renewed sickle cell investment lifts a once-shirked disease

    Pfizer's $5.4 billion deal to acquire Global Blood Therapeutics invigorated the fast-growing market, and patients are fit to be the benefactors.

    By Kelly Bilodeau • Sept. 1, 2022
  • Glass vials of Moderna COVID-19 vaccine.
    Image attribution tooltip
    Gabriel Kuchta via Getty Images
    Image attribution tooltip

    Moderna’s lawsuit against Pfizer and BioNTech explained in 10 quotes

    The biotech says that its competitors’ COVID-19 vaccine copied proprietary mRNA technology. Here’s a breakdown of the case.

    By Karissa Waddick • Aug. 31, 2022